 Cytochrome P-450 CYP2D6
"Cytochrome P-450 CYP2D6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR ANTAGONISTS; and TRICYCLIC ANTIDEPRESSANTS. This enzyme is deficient in up to 10 percent of the Caucasian population.
| Descriptor ID |
D019389
|
| MeSH Number(s) |
D08.244.453.040.600 D08.811.682.690.708.170.040.600 D12.776.422.220.453.040.600
|
| Concept/Terms |
Cytochrome P-450 CYP2D6- Cytochrome P-450 CYP2D6
- CYP2D6, Cytochrome P-450
- Cytochrome P 450 CYP2D6
- P-450 CYP2D6, Cytochrome
- CYP2D6
- Cytochrome P450 2D6
- P450 2D6, Cytochrome
- Sparteine Monooxygenase
- Monooxygenase, Sparteine
- Debrisoquine 4-Monooxygenase
- 4-Monooxygenase, Debrisoquine
- Debrisoquine 4 Monooxygenase
- Debrisoquine Hydroxylase
- Hydroxylase, Debrisoquine
- Imipramine 2-Hydroxylase
- 2-Hydroxylase, Imipramine
- Imipramine 2 Hydroxylase
- CYP 2D6
- Debrisoquine 4-Hydroxylase
- 4-Hydroxylase, Debrisoquine
- Debrisoquine 4 Hydroxylase
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2D6".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2D6".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2D6" by people in this website by year, and whether "Cytochrome P-450 CYP2D6" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 4 | 0 | 4 | | 1999 | 2 | 2 | 4 | | 2000 | 2 | 0 | 2 | | 2001 | 0 | 1 | 1 | | 2002 | 3 | 1 | 4 | | 2003 | 3 | 1 | 4 | | 2004 | 2 | 1 | 3 | | 2005 | 4 | 0 | 4 | | 2006 | 2 | 2 | 4 | | 2007 | 3 | 2 | 5 | | 2008 | 4 | 2 | 6 | | 2010 | 5 | 0 | 5 | | 2011 | 4 | 1 | 5 | | 2012 | 1 | 1 | 2 | | 2013 | 7 | 0 | 7 | | 2014 | 7 | 0 | 7 | | 2015 | 5 | 0 | 5 | | 2016 | 4 | 0 | 4 | | 2017 | 4 | 0 | 4 | | 2018 | 5 | 0 | 5 | | 2019 | 7 | 1 | 8 | | 2020 | 3 | 4 | 7 | | 2021 | 11 | 2 | 13 | | 2022 | 3 | 1 | 4 | | 2023 | 3 | 2 | 5 | | 2024 | 3 | 4 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2D6" by people in Profiles.
-
Bishop JR, Zhou C, Gaedigk A, Krone B, Kittles R, Cook EH, Newcorn JH, Stein MA. Dopamine Transporter and CYP2D6 Gene Relationships with Attention-Deficit/Hyperactivity Disorder Treatment Response in the Methylphenidate and Atomoxetine Crossover Study. J Child Adolesc Psychopharmacol. 2024 12; 34(10):458-469.
-
Duarte JD, Thomas CD, Lee CR, Huddart R, Agundez JAG, Baye JF, Gaedigk A, Klein TE, Lanfear DE, Monte AA, Nagy M, Schwab M, Stein CM, Uppugunduri CRS, van Schaik RHN, Donnelly RS, Caudle KE, Luzum JA. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC)?for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy. Clin Pharmacol Ther. 2024 Oct; 116(4):939-947.
-
Tang Girdwood S, Hall M, Antoon JW, Kyler KE, Williams DJ, Shah SS, Orth LE, Goldman J, Feinstein JA, Ramsey LB. Opportunities for Pharmacogenetic Testing to Guide Dosing of Medications in Youths With Medicaid. JAMA Netw Open. 2024 02 05; 7(2):e2355707.
-
Honeycutt DC, Blom TJ, Ramsey LB, Strawn JR, Bruns KM, Welge JA, Patino LR, Singh MK, DelBello MP. Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study. J Child Adolesc Psychopharmacol. 2024 02; 34(1):42-51.
-
Kanu AA, Johnston MM, Poweleit EA, Vaughn SE, Strawn JR, Ramsey LB. Influence of CYP2D6 Metabolizer Status on Risperidone and Paliperidone Tolerability in Children and Adolescents. J Child Adolesc Psychopharmacol. 2024 02; 34(1):34-41.
-
Men X, Taylor ZL, Marshe VS, Blumberger DM, Karp JF, Kennedy JL, Lenze EJ, Reynolds CF, Stefan C, Mulsant BH, Ramsey LB, M?ller DJ. CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression. Clin Pharmacol Ther. 2024 May; 115(5):1065-1074.
-
Cheng S, Al-Kofahi M, Leeder JS, Brown JT. Population Pharmacokinetic Analysis of Atomoxetine and its Metabolites in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Clin Pharmacol Ther. 2024 May; 115(5):1033-1043.
-
Goodson R, Wagner J, Sandritter T, Staggs VS, Soden S, Nadler C. Pharmacogenetic Testing in Patients with Autism Spectrum Disorder Evaluated in a Precision Medicine Clinic. J Dev Behav Pediatr. 2023 Oct-Nov 01; 44(8):e505-e510.
-
Turner AJ, Nofziger C, Ramey BE, Ly RC, Bousman CA, Ag?ndez JAG, Sangkuhl K, Whirl-Carrillo M, Vanoni S, Dunnenberger HM, Rua?o G, Kennedy MA, Phillips MS, Hachad H, Klein TE, Moyer AM, Gaedigk A. PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting. Clin Pharmacol Ther. 2023 12; 114(6):1220-1237.
-
Ramsey LB, Prows CA, Chidambaran V, Sadhasivam S, Quinn CT, Teusink-Cross A, Tang Girdwood S, Dawson DB, Vinks AA, Glauser TA. Implementation of CYP2D6-guided opioid therapy at Cincinnati Children's Hospital Medical Center. Am J Health Syst Pharm. 2023 06 22; 80(13):852-859.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|